Cited 5 times in
Effect of renin-angiotensin system inhibitors on major clinical outcomes in patients with acute myocardial infarction and prediabetes or diabetes after successful implantation of newer-generation drug-eluting stents
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고영국 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 김중선 | - |
dc.contributor.author | 안철민 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 홍명기 | - |
dc.contributor.author | 홍성진 | - |
dc.date.accessioned | 2022-09-02T01:13:59Z | - |
dc.date.available | 2022-09-02T01:13:59Z | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 1056-8727 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190081 | - |
dc.description.abstract | Aim: To investigate the comparative effectiveness of renin-angiotensin system inhibitor (RASI) therapy on major clinical outcomes in patients with acute myocardial infarction (AMI) and prediabetes or diabetes after successful percutaneous coronary intervention (PCI) with newer-generation drug-eluting stents (DESs). Methods: A total of 11,962 patients with AMI were divided into six groups according to glycemic status and the presence or absence of RASI therapy: normoglycemia (n = 3,080; RASI- [n = 2,496], RASI- [n = 584]), prediabetes (n = 3,709; RASI- [n = 2,9441, RASI- [n = 765]), and diabetes (n = 5,173; RASI- [n = 4,1331, RASI- [n 1,040]). The major endpoint was major adverse cardiac events (MACEs), defined as all-cause death, recurrent myocardial infarction (re-MI), or any repeat revascularization. Results: After adjustment, in RASI users, the cumulative incidence of re-MI of the diabetes group was significantly higher than that of the prediabetes group (aHR, 1.999; 95% CI, 1.153-3.467; p- 0.014). However, the cumulative incidences of MACEs, all-cause death, and any repeat revascularization were similar between the two groups during a 2-year follow-up period. Conclusions: In the era of newer-generation DESs, RASI therapy did not reduce re-MI in patients with AMI and diabetes in this study. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier Science Pub. Co. | - |
dc.relation.isPartOf | JOURNAL OF DIABETES AND ITS COMPLICATIONS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Angiotensin Receptor Antagonists / therapeutic use* | - |
dc.subject.MESH | Angiotensin-Converting Enzyme Inhibitors / therapeutic use* | - |
dc.subject.MESH | Diabetes Complications / complications* | - |
dc.subject.MESH | Drug-Eluting Stents* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Myocardial Infarction / complications | - |
dc.subject.MESH | Myocardial Infarction / therapy* | - |
dc.subject.MESH | Percutaneous Coronary Intervention | - |
dc.subject.MESH | Prediabetic State / complications* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | Effect of renin-angiotensin system inhibitors on major clinical outcomes in patients with acute myocardial infarction and prediabetes or diabetes after successful implantation of newer-generation drug-eluting stents | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yong Hoon Kim | - |
dc.contributor.googleauthor | Ae-Young Her | - |
dc.contributor.googleauthor | Myung Ho Jeong | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Sung-Jin Hong | - |
dc.contributor.googleauthor | Seunghwan Kim | - |
dc.contributor.googleauthor | Chul-Min Ahn | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.contributor.googleauthor | Young-Guk Ko | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.identifier.doi | 10.1016/j.jdiacomp.2020.107574 | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A02269 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A04391 | - |
dc.contributor.localId | A04403 | - |
dc.relation.journalcode | J01376 | - |
dc.identifier.eissn | 1873-460X | - |
dc.identifier.pmid | 32147394 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1056872719314643 | - |
dc.subject.keyword | Renin-angiotensin system | - |
dc.subject.keyword | Prediabetes | - |
dc.subject.keyword | Diabetes | - |
dc.subject.keyword | Outcomes | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.affiliatedAuthor | 고영국 | - |
dc.contributor.affiliatedAuthor | 김병극 | - |
dc.contributor.affiliatedAuthor | 김중선 | - |
dc.contributor.affiliatedAuthor | 안철민 | - |
dc.contributor.affiliatedAuthor | 장양수 | - |
dc.contributor.affiliatedAuthor | 최동훈 | - |
dc.contributor.affiliatedAuthor | 홍명기 | - |
dc.contributor.affiliatedAuthor | 홍성진 | - |
dc.citation.volume | 34 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 107574 | - |
dc.identifier.bibliographicCitation | JOURNAL OF DIABETES AND ITS COMPLICATIONS, Vol.34(6) : 107574, 2020-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.